Regulus Therapeutics Inc

NASDAQ:RGLS   3:58:11 PM EDT
0.91
+0.03 (+3.85%)
Products, Regulatory

Regulus Therapeutics Announces Top-Line Data From First Cohort Of Phase 1B Clinical Trial Of RGLS4326

Published: 05/03/2021 13:22 GMT
Regulus Therapeutics Inc (RGLS) - Regulus Therapeutics Announces Top-line Data From the First Cohort of Phase 1b Clinical Trial of Rgls4326 for the Treatment of Patients With Autosomal Dominant Polycystic Kidney Disease (adpkd).
Regulus Therapeutics Inc - Statistically Significant Increase in Polycystin 1 Biomarker Observed by End of Study.
Regulus Therapeutics Inc - Demonstrated Pharmacokinetic Profile Similar to Healthy Volunteers.
Regulus Therapeutics Inc - Rgls4326 Was Well Tolerated by All Nine Patients With No Serious Adverse Events Reported.